omeprazole has been researched along with Sepsis in 5 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Omeprazole (OMZ) is a proton pump inhibitor that is used to reduce gastric acid secretion, but little is known about its possible liver protective effects." | 5.72 | Omeprazole Increases Survival Through the Inhibition of Inflammatory Mediaters in Two Rat Sepsis Models. ( Hashimoto, Y; Hatta, M; Kaibori, M; Kotsuka, M; Nakatake, R; Nishizawa, M; Okumura, T; Okuyama, T; Sekimoto, M; Yoshida, T, 2022) |
| "Omeprazole (OMZ) is a proton pump inhibitor that is used to reduce gastric acid secretion, but little is known about its possible liver protective effects." | 1.72 | Omeprazole Increases Survival Through the Inhibition of Inflammatory Mediaters in Two Rat Sepsis Models. ( Hashimoto, Y; Hatta, M; Kaibori, M; Kotsuka, M; Nakatake, R; Nishizawa, M; Okumura, T; Okuyama, T; Sekimoto, M; Yoshida, T, 2022) |
| "Especially patients with severe sepsis or septic shock are prone to develop lesions of the upper gastrointestinal tract with consecutive bleeding." | 1.35 | [Stress ulcer prophylaxis in septic patients. Evidence-based overview]. ( Elke, G; Schädler, D; Scholz, J; Weiler, N; Zick, G, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kotsuka, M | 1 |
| Hashimoto, Y | 1 |
| Nakatake, R | 1 |
| Okuyama, T | 1 |
| Hatta, M | 1 |
| Yoshida, T | 1 |
| Okumura, T | 1 |
| Nishizawa, M | 1 |
| Kaibori, M | 1 |
| Sekimoto, M | 1 |
| Roa Colomo, A | 1 |
| García Robles, A | 1 |
| Ruiz Escolano, E | 1 |
| Furr, M | 1 |
| Cohen, ND | 1 |
| Axon, JE | 1 |
| Sanchez, LC | 1 |
| Pantaleon, L | 1 |
| Haggett, E | 1 |
| Campbell, R | 1 |
| Tennent-Brown, B | 1 |
| Yarze, JC | 1 |
| Elke, G | 1 |
| Schädler, D | 1 |
| Zick, G | 1 |
| Scholz, J | 1 |
| Weiler, N | 1 |
5 other studies available for omeprazole and Sepsis
| Article | Year |
|---|---|
Omeprazole Increases Survival Through the Inhibition of Inflammatory Mediaters in Two Rat Sepsis Models.
Topics: Animals; Cell Culture Techniques; Disease Models, Animal; Galactosamine; Hepatectomy; Hepatocytes; I | 2022 |
Black esophagus, is it as bad as it seems?
Topics: Alcoholism; Colonic Pseudo-Obstruction; Esophagitis; Esophagoscopy; Food, Formulated; Gastrointestin | 2019 |
Treatment with histamine-type 2 receptor antagonists and omeprazole increase the risk of diarrhoea in neonatal foals treated in intensive care units.
Topics: Animals; Animals, Newborn; Anti-Ulcer Agents; Clostridium Infections; Diarrhea; Female; Histamine H2 | 2012 |
Septic complications after variceal cyanoacrylate injection.
Topics: Anti-Ulcer Agents; Cyanoacrylates; Esophageal and Gastric Varices; Hemostasis, Endoscopic; Humans; O | 2005 |
[Stress ulcer prophylaxis in septic patients. Evidence-based overview].
Topics: Anti-Ulcer Agents; Cimetidine; Duodenal Ulcer; Evidence-Based Medicine; Gastric Acid; Gastrointestin | 2008 |